Evidence map›Paper›PMID 20385986›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

David Marin, Alexandra Bazeos, Francois-Xavier Mahon, Lina Eliasson, Dragana Milojkovic, Marco Bua, Jane F Apperley, Richard Szydlo, Ritti Desai, Kasia Kozlowski and 10 more

4 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 366 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
366citing papers in PubMed, 4 pooled it
39.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00632255 completednot on this map

Compliance to Long Term Imatinib Therapy in Newly Diagnosed Patients With Chronic Myeloid Leukaemia.

TypeobservationalSponsorImperial College LondonRan2008 to 2009Enrolled88ConditionsChronic Myeloid Leukemia, Newly DiagnosedArmsImatinib
NCT01768689 nacompletednot on this mapstarted 2013, after this paper: background citation

The Effect of Active Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - A Prospective Observational Multicenter Study (TAKE-IT)

TypeinterventionalSponsorpia raananiRan2013 to 2015Enrolled58ConditionsLeukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication AdherenceArmsAdherence-encouraging interventions - Group meeting, Adherence-encouraging interventions - Individual meetings, Adherence-encouraging interventions - Monthly phone calls
NCT03090477 nacompletednot on this mapstarted 2017, after this paper: background citation

Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients. A Randomised Control Trial

TypeinterventionalSponsorUCSI UniversityRan2017 to 2019Enrolled129ConditionsLeukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication AdherenceArmsPharmaceutical care and adherence aids
NCT04384848 nacompletednot on this mapstarted 2019, after this paper: background citation

Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients With Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: The EMPATHY Pilot Study

TypeinterventionalSponsorNorthwestern UniversityRan2019 to 2022Enrolled94ConditionsLeukemia, Chronic Myeloid, CancerArmsEMPATHY Pilot
3 · Its place in the literature

Who cites it

366 citing papers in PubMed, 4 syntheses or guidelines pooled it, 893 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Psychometric evaluation of the PROMISJournal of patient-reported outcomes · 2026
    Observational
  19. Article
  20. Article

306 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

David MarinDepartment of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom. d.marin@imperial.ac.uk
Alexandra Bazeos
Francois-Xavier Mahon
Lina Eliasson
Dragana Milojkovic
Marco Bua
Jane F Apperley
Richard Szydlo
Ritti Desai
Kasia Kozlowski
Christos Paliompeis
Victoria Latham
Letizia Foroni
Mathieu Molimard
Alistair Reid
Katy Rezvani
Hugues de Lavallade
Cristina Guallar
John Goldman
Jamshid S Khorashad
Imperial College London · GB

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

purposeThere is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence.

methodsEighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed.

resultsMedian adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence <or= 90%; in 12 of these patients (14%), adherence was <or= 80%. There was a strong correlation between adherence rate (<or= 90% or > 90%) and the 6-year probability of a 3-log reduction (also known as major molecular response [MMR]) in BCR-ABL1 transcripts (28.4% v 94.5%; P < .001) and also complete molecular response (CMR; 0% v 43.8%; P = .002). Multivariate analysis identified adherence (relative risk [RR], 11.7; P = .001) and expression of the molecular human organic cation transporter-1 (RR, 1.79; P = .038) as the only independent predictors for MMR. Adherence was the only independent predictor for CMR. No molecular responses were observed when adherence was <or= 80% (P < .001). Patients whose imatinib doses were increased had poor adherence (86.4%). In this latter population, adherence was the only independent predictor for inability to achieve an MMR (RR, 17.66; P = .006).

conclusionIn patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses.

Indexed as

Cytogenetic AnalysisGene Expression Regulation, LeukemicMedication AdherenceAdultAgedAged, 80 and overAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1BenzamidesDrug MonitoringFemaleFusion Proteins, bcr-ablHumansImatinib MesylateKaplan-Meier EstimateABCB1 protein, humanabl-bcr fusion protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1BenzamidesFusion Proteins, bcr-ablImatinib MesylateOctamer Transcription Factor-1PiperazinesPOU2F1 protein, humanProtein Kinase InhibitorsPyrimidinesRNA, Messenger

Identifiers

PMID20385986
PMCPMC6366340
OpenAlexW2166270808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.